Thermo Fisher expands into gene therapy in $1.7bn deal

Biotech company Thermo Fisher Scientific has announced plans to acquire Brammer Bio, a viral vector manufacturer for gene and cell therapies, for $1.7 billion.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Thermo Fisher to acquire electron microscopy company for $4.2bn

31 May 2016 Thermo Fisher Scientific has announced that it will buy FEI, an electron microscopy company, for $4.2 billion.

Americas

Catalent to buy $1.2bn gene therapy company

17 April 2019 Contract drug manufacturer Catalent has agreed to acquire Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion.

Big Pharma

Thermo Fisher to buy Qiagen for $11.5bn

3 March 2020 Biotech Thermo Fisher Scientific has announced plans to acquire Dutch diagnostics group Qiagen for $11.5 billion.

More on this story

Americas

Thermo Fisher to acquire electron microscopy company for $4.2bn

31 May 2016 Thermo Fisher Scientific has announced that it will buy FEI, an electron microscopy company, for $4.2 billion.

Americas

Catalent to buy $1.2bn gene therapy company

17 April 2019 Contract drug manufacturer Catalent has agreed to acquire Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion.

Big Pharma

Thermo Fisher to buy Qiagen for $11.5bn

3 March 2020 Biotech Thermo Fisher Scientific has announced plans to acquire Dutch diagnostics group Qiagen for $11.5 billion.

More on this story

Americas

Thermo Fisher to acquire electron microscopy company for $4.2bn

31 May 2016 Thermo Fisher Scientific has announced that it will buy FEI, an electron microscopy company, for $4.2 billion.

Americas

Catalent to buy $1.2bn gene therapy company

17 April 2019 Contract drug manufacturer Catalent has agreed to acquire Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion.

Big Pharma

Thermo Fisher to buy Qiagen for $11.5bn

3 March 2020 Biotech Thermo Fisher Scientific has announced plans to acquire Dutch diagnostics group Qiagen for $11.5 billion.